Healthcare provider profile · identity verified

Ramon M Ansa Vila, M.D.

Allopathic & Osteopathic Physicians|General Practice · CANOVANAS, PR · NPI 1225259047

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Ramon M Ansa Vila, M.D. received $112.87 in general payments during 2025 across 2 reported records.

Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 77.8% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.

AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Synjardy by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$112.87

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$87.87	77.8%	1	2025
AstraZeneca Pharmaceuticals LP	Unresolved — no canonical attribution shown	$25.00	22.1%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$112.87	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
JARDIANCE Normalized: jardiance	Drug	Boehringer Ingelheim Pharmaceuticals, Inc.	$87.87	1	2025
Source payment records 2025-03-12 · Boehringer Ingelheim Pharmaceuticals, Inc. · $87.87 · Open Payments source
AIRSUPRA Normalized: airsupra	Drug	AstraZeneca Pharmaceuticals LP	$25.00	1	2025
Source payment records 2025-08-12 · AstraZeneca Pharmaceuticals LP · $25.00 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
JARDIANCE jardiance	2025	Jardiance	2024	36	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	BRILINTA open payments reported associated product	CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430	Brilinta · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference	2025	FARXIGA open payments reported associated product	CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362	Farxiga · 2024 Exact normalized brand match · 1 Part D row	35	suppressed by CMS
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	36	11
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	SYNJARDY open payments reported associated product	CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005	Synjardy · 2024 Exact normalized brand match · 1 Part D row	16	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Gabapentin	Gabapentin	404	143
Atorvastatin Calcium	Atorvastatin Calcium	381	147
Simvastatin	Simvastatin	364	138
Losartan Potassium	Losartan Potassium	347	118
Montelukast Sodium	Montelukast Sodium	304	181
Omeprazole	Omeprazole	278	77
Famotidine	Famotidine	259	91
Synthroid	Levothyroxine Sodium	256	83
Amlodipine Besylate	Amlodipine Besylate	255	88
Metoprolol Succinate	Metoprolol Succinate	235	83
Metformin Hcl	Metformin Hcl	230	82
Tramadol Hcl	Tramadol Hcl	226	41
Tizanidine Hcl	Tizanidine Hcl	214	141
Lisinopril	Lisinopril	204	72
Azithromycin	Azithromycin	180	136
Diclofenac Sodium	Diclofenac Sodium	162	88
Pregabalin	Pregabalin	153	93
Levothyroxine Sodium	Levothyroxine Sodium	152	57
Glimepiride	Glimepiride	145	47
Pantoprazole Sodium	Pantoprazole Sodium	145	44
Dexamethasone	Dexamethasone	144	112
Lantus	Insulin Glargine,hum.Rec.Anlog	130	24
Nabumetone	Nabumetone	129	74
Hydrochlorothiazide	Hydrochlorothiazide	123	41
Alprazolam	Alprazolam	118	19
Tamsulosin Hcl	Tamsulosin Hcl	114	39
Trijardy Xr	Empaglifloz/Linaglip/Metformin	114	22
Rosuvastatin Calcium	Rosuvastatin Calcium	113	60
Triamcinolone Acetonide	Triamcinolone Acetonide	112	83
Meclizine Hcl	Meclizine Hcl	109	59
Temazepam	Temazepam	106	27
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	103	58
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	97	33
Clonazepam	Clonazepam	94	31
Baclofen	Baclofen	92	60
Lorazepam	Lorazepam	90	19
Trazodone Hcl	Trazodone Hcl	83	45
Fenofibrate	Fenofibrate	82	31
Sucralfate	Sucralfate	82	50
Humalog	Insulin Lispro	81	14
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	78	15
Sertraline Hcl	Sertraline Hcl	78	28
Pentoxifylline	Pentoxifylline	70	34
Diclofenac Potassium	Diclofenac Potassium	68	43
Ketorolac Tromethamine	Ketorolac Tromethamine	68	44
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	67	45
Prednisone	Prednisone	67	58
Quetiapine Fumarate	Quetiapine Fumarate	67	19
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	65	21
Ciprofloxacin Hcl	Ciprofloxacin Hcl	64	55
Betamethasone Valerate	Betamethasone Valerate	63	56
Glipizide	Glipizide	62	21
Albuterol Sulfate	Albuterol Sulfate	61	55
Finasteride	Finasteride	61	22
Doxycycline Hyclate	Doxycycline Hyclate	60	53
Fluticasone Propionate	Fluticasone Propionate	60	35
Furosemide	Furosemide	59	26
Clopidogrel	Clopidogrel Bisulfate	58	22
Janumet	Sitagliptin Phos/Metformin Hcl	57	21
Donepezil Hcl	Donepezil Hcl	56	22
Ketoconazole	Ketoconazole	53	31
Cilostazol	Cilostazol	52	19
Buspirone Hcl	Buspirone Hcl	51	23
Enulose	Lactulose	51	22
Irbesartan	Irbesartan	49	19
Acyclovir	Acyclovir	47	27
Piroxicam	Piroxicam	47	38
Oxybutynin Chloride Er	Oxybutynin Chloride	46	18
Neomycin-Polymyxin-Hydrocort	Neomycin/Polymyxin B/Hydrocort	45	38
Alendronate Sodium	Alendronate Sodium	44	14
Levofloxacin	Levofloxacin	44	40
Glipizide Er	Glipizide	43	14
Clindamycin Hcl	Clindamycin Hcl	42	37
Eliquis	Apixaban	41	13
Carvedilol	Carvedilol	40	16
Doxazosin Mesylate	Doxazosin Mesylate	40	16
Enalapril Maleate	Enalapril Maleate	40	15
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	40	36
Isosorbide Mononitrate Er	Isosorbide Mononitrate	39	12
Cetirizine Hcl	Cetirizine Hcl	38	36
Memantine Hcl	Memantine Hcl	37	15
Jardiance	Empagliflozin	36	11
Farxiga	Dapagliflozin Propanediol	35	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	35	30
Allopurinol	Allopurinol	34	14
Humulin N	Insulin Nph Human Isophane	34	suppressed
Sulindac	Sulindac	34	24
Sure Comfort	Syringe And Needle,insulin,1ml	34	suppressed
Endocet	Oxycodone Hcl/Acetaminophen	33	suppressed
Xarelto	Rivaroxaban	33	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	29	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	29	suppressed
Atenolol	Atenolol	28	suppressed
Memantine Hcl Er	Memantine Hcl	28	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	27	14
Etodolac Er	Etodolac	27	24
Metoprolol Tartrate	Metoprolol Tartrate	27	suppressed
Mupirocin	Mupirocin	26	25
Sildenafil Citrate	Sildenafil Citrate	26	suppressed
Januvia	Sitagliptin Phosphate	25	suppressed
Nifedipine Er	Nifedipine	25	suppressed
Clonidine Hcl	Clonidine Hcl	24	suppressed
Ibandronate Sodium	Ibandronate Sodium	24	suppressed
Ibuprofen	Ibuprofen	24	12
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	24	20
Spironolactone	Spironolactone	24	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	23	13
Zolpidem Tartrate	Zolpidem Tartrate	23	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	22	13
Fluconazole	Fluconazole	22	20
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	22	suppressed
Lactulose	Lactulose	22	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	22	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	21	20
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	21	suppressed
Celecoxib	Celecoxib	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Latanoprost	Latanoprost	21	suppressed
Chlorthalidone	Chlorthalidone	19	suppressed
Ciclopirox	Ciclopirox	19	15
Loperamide	Loperamide Hcl	19	suppressed
Orphenadrine Citrate	Orphenadrine Citrate	19	15
Verapamil Er	Verapamil Hcl	19	suppressed
Cefadroxil	Cefadroxil	18	14
Janumet Xr	Sitagliptin Phos/Metformin Hcl	18	suppressed
Oseltamivir Phosphate	Oseltamivir Phosphate	18	18
Pravastatin Sodium	Pravastatin Sodium	18	suppressed
Trueplus Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	18	suppressed
Levetiracetam	Levetiracetam	17	suppressed
Procto-Med Hc	Hydrocortisone	17	12
Sure Comfort	Syringe-Needle,insulin,0.5 Ml	17	suppressed
Bupropion Hcl Sr	Bupropion Hcl	16	suppressed
Humulin R	Insulin Regular, Human	16	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	16	suppressed
Synjardy	Empagliflozin/Metformin Hcl	16	suppressed
Candesartan-Hydrochlorothiazid	Candesartan/Hydrochlorothiazid	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	15	suppressed
Methimazole	Methimazole	15	suppressed
Metronidazole	Metronidazole	15	13
Oxybutynin Chloride	Oxybutynin Chloride	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Ramipril	Ramipril	15	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	14	suppressed
Methotrexate	Methotrexate Sodium	14	suppressed
Naproxen	Naproxen	14	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	14	suppressed
Chlorzoxazone	Chlorzoxazone	13	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	13	suppressed
Desloratadine	Desloratadine	13	suppressed
Diltiazem Hcl	Diltiazem Hcl	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Bethanechol Chloride	Bethanechol Chloride	12	suppressed
Duloxetine Hcl	Duloxetine Hcl	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Sure Comfort	Syring-Needl,disp,insul,0.3 Ml	12	suppressed
Brilinta	Ticagrelor	11	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	11	suppressed
Lamotrigine	Lamotrigine	11	suppressed
Prednisolone Sodium Phosphate	Prednisolone Sodium Phosphate	11	suppressed
Trandolapril-Verapamil Er	Trandolapril/Verapamil Hcl	11	suppressed
Valsartan	Valsartan	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$112.87 · 2 records	Boehringer Ingelheim Pharmaceuticals, Inc.	AIRSUPRA, JARDIANCE	4	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Jardiance play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error